Skip to main content

Roivant Sciences Ltd.

For the period ended Mar 31, 2025. Filed May 29, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed May 29, 2025

ROIV$40.67+4.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Roivant Sciences Ltd.
Date: May 29, 2025By:/s/ Keyur Parekh
Name: Keyur Parekh
Title: Authorized Signatory

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Richard Pulik, Jo Chen and Keyur Parekh, as their true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to the Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Matthew GlineChief Executive Officer and Director (Principal Executive Officer)May 29, 2025
Matthew Gline
/s/ Richard PulikChief Financial Officer (Principal Financial Officer)May 29, 2025
Richard Pulik
/s/ Jennifer HumesChief Accounting Officer (Principal Accounting Officer)May 29, 2025
Jennifer Humes
/s/ Mayukh SukhatmePresident and Chief Investment Officer and DirectorMay 29, 2025
Mayukh Sukhatme
/s/ Keith ManchesterDirectorMay 29, 2025
Keith Manchester
/s/ Ilan OrenDirectorMay 29, 2025
Ilan Oren
/s/ Daniel GoldDirectorMay 29, 2025
Daniel Gold
/s/ Melissa EpperlyDirectorMay 29, 2025
Melissa Epperly
/s/ Meghan FitzGeraldDirectorMay 29, 2025
Meghan FitzGerald
/s/ James C. MomtazeeDirectorMay 29, 2025
James C. Momtazee
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.